Axsome recently had a Phase 3 trial of AXS-02 for complex regional pain syndrome stopped due to futility.
While Axsome has multiple other compounds and potential indications, there are significant concerns with many of those currently in Phase 2/3.
Axsome heavily relies on combination drugs that have limited internal innovation.
The most innovative ideas from Axsome are in Phase 1 from their MoSEIC technology.
AXS-02 Failure in Complex Regional Pain Syndrome
Axsome Therapeutics (AXSM) is a developmental biotech that currently has a diverse list of targets, including bone pain, treatment resistant depression, smoking cessation, migraine headaches, and